查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951807

下一代疫苗技術市場分析及預測（至2035年）：按類型、產品類型、技術、應用、最終用戶、組件、設備、製程、部署類型和解決方案分類

Next-Generation Vaccination Technologies Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Component, Device, Process, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 307 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計下一代疫苗技術市場將從2024年的342億美元成長到2034年的2,028億美元，複合年成長率約為23.7%。該市場涵蓋了疫苗研發和給藥的先進方法，包括mRNA平台、病毒載體和奈米顆粒系統。這些創新技術旨在提高疫苗的有效性、安全性和生產速度。對快速應對新興感染疾病、個人化疫苗接種策略以及提高全球疫苗可及性的需求不斷成長，正在推動市場成長。關鍵趨勢包括佐劑、熱穩定性以及無針給藥系統等方面的技術進步，這些進步有助於克服疫苗分發和給藥方面的挑戰。

下一代疫苗技術市場預計將迎來顯著成長，這主要得益於生物技術創新和全球健康意識的不斷提高。 mRNA疫苗憑藉其快速的研發能力和對多種病原體的適應性，在性能方面佔據主導地位。 DNA疫苗緊隨其後，這主要歸功於其穩定性和易於生產的優勢。佐劑技術在疫苗遞送系統領域中日益受到重視，因為它能夠增強疫苗的效力和免疫抗原性。病毒載體疫苗也備受關注，尤其是誘發強效免疫反應的能力。基於奈米顆粒的遞送系統正成為實現標靶和可控疫苗遞送的一個極具前景的領域。低溫運輸物流和儲存解決方案的創新正在確保疫苗的效力和供應，從而進一步推動市場擴張。人工智慧驅動的分析和數據管理平台等數位健康技術的整合正在最佳化疫苗的分發和監測，為相關人員帶來盈利的機會。

市場區隔
按類型 重組疫苗、DNA疫苗、RNA疫苗、次單位疫苗、載體疫苗、減毒活病毒疫苗、去活化疫苗、合成疫苗
產品 疫苗製劑、佐劑、疫苗接種裝置、疫苗包裝、疫苗儲存方案
科技 奈米顆粒技術、類病毒顆粒、偶聯技術、基因編輯、合成生物學、反向疫苗學
應用領域 感染疾病、癌症疫苗、過敏疫苗、自體免疫疾病、神經系統疾病
最終用戶 醫院、診所、研究機構、生物製藥公司、政府機構
成分 抗原、穩定劑、防腐劑、佐劑
裝置 無針注射器、微針貼片、口服給藥系統、吸入裝置
過程 發酵、細胞培養、純化、配方
實施表格 本機部署、雲端部署、混合式部署
解決方案 低溫運輸管理、疫苗追蹤系統

下一代疫苗技術市場的特點是市場佔有率波動劇烈，各公司透過策略定價和創新產品推出爭奪主導。競爭格局的特點是新參與企業數量迅速成長，每個新進入者都提供尖端解決方案，承諾提高疫苗的有效性和安全性。現有企業正利用其市場地位推出先進疫苗，以滿足日益成長的有效疫苗需求。應對新興感染疾病的需求進一步加劇了這種競爭格局，推動了持續的創新和適應。在競爭基準評估方面，領先的製藥公司主要根據其技術進步和策略聯盟進行評估。監管影響至關重要，北美和歐洲的嚴格指導方針對市場准入和擴張起著決定性作用。在基因研究和生物技術進步的推動下，市場正朝著個人化疫苗解決方案發展。人工智慧和數據分析的整合正在提升疫苗研發流程，使企業處於技術創新的前沿。對於願意應對監管複雜性並投資於研發的利害關係人相關人員，這種格局蘊藏著盈利機會。

主要趨勢和促進因素：

下一代疫苗技術市場正經歷強勁成長，這主要得益於生物技術的進步以及研發投入的不斷增加。關鍵趨勢包括mRNA疫苗的研發，由於其研發速度快、療效高，正日益受到關注。根據個體基因譜量身定做的個人化疫苗也正在蓬勃發展，提供更有效的免疫策略。另一個重要趨勢是將人工智慧（AI）和機器學習應用於疫苗研發，從而加速篩選出有前景的候選疫苗。推動市場成長的因素包括應對疫情的迫切性以及全球對更有效率、擴充性的疫苗生產方法的需求。感染疾病的日益普及以及對創新疫苗解決方案的需求進一步推動了市場成長。新興市場蘊藏著許多機遇，政府主導的措施和國際合作正在擴大疫苗接種覆蓋範圍。投資下一代平台和技術的公司將能夠更好地掌握這些新機會。此外，著力改善疫苗分發和儲存，尤其是在偏遠地區，也為市場開闢了新的成長途徑。隨著世界各國繼續將健康安全放在首位，下一代疫苗技術市場預計將持續擴張。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 重組疫苗
    • DNA疫苗
    • RNA疫苗
    • 次單位疫苗
    • 基於載體的疫苗
    • 減毒活病毒疫苗
    • 去活化疫苗
    • 合成疫苗
  • 市場規模及預測：依產品分類
    • 疫苗製劑
    • 佐劑
    • 疫苗輸送裝置
    • 疫苗包裝
    • 疫苗儲存方案
  • 市場規模及預測：依技術分類
    • 奈米顆粒技術
    • 類病毒顆粒
    • 組合技術
    • 基因編輯
    • 合成生物學
    • 反向疫苗學
  • 市場規模及預測：依應用領域分類
    • 感染疾病
    • 癌症疫苗
    • 過敏疫苗
    • 自體免疫疾病
    • 神經系統疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究所
    • 生物製藥公司
    • 政府機構
  • 市場規模及預測：依組件分類
    • 抗原
    • 穩定器
    • 防腐劑
    • 佐劑
  • 市場規模及預測：依設備分類
    • 無針注射器
    • 微針貼片
    • 口服給藥系統
    • 吸入裝置
  • 市場規模及預測：依製程分類
    • 發酵
    • 細胞培養
    • 純化
    • 配方
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
    • 混合
  • 市場規模及預測：按解決方案分類
    • 低溫運輸管理
    • 疫苗追蹤系統

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Cure Vac
  • Valneva
  • Novavax
  • Inovio Pharmaceuticals
  • Vaxart
  • Geo Vax Labs
  • Moderna
  • Bio NTech
  • Dynavax Technologies
  • Bavarian Nordic
  • Arcturus Therapeutics
  • Immunomic Therapeutics
  • Medicago
  • Altimmune
  • Emergent Bio Solutions
  • Gritstone Oncology
  • Sorrento Therapeutics
  • Translate Bio
  • Vir Biotechnology
  • Icosavax

第9章：關於我們

簡介目錄
Product Code: GIS32951

Next-Generation Vaccination Technologies Market is anticipated to expand from $34.2 billion in 2024 to $202.8 billion by 2034, growing at a CAGR of approximately 23.7%. The Next-Generation Vaccination Technologies Market encompasses advanced methods for vaccine development and delivery, including mRNA platforms, viral vectors, and nanoparticle-based systems. These innovations aim to enhance efficacy, safety, and production speed. The market is propelled by increasing demand for rapid response to emerging infectious diseases, personalized immunization strategies, and improved global vaccine access. Key trends include technological advancements in adjuvants, thermostability, and needle-free delivery systems, addressing challenges in distribution and administration.

The Next-Generation Vaccination Technologies Market is poised for substantial growth, driven by advancements in biotechnological innovations and increasing global health awareness. The mRNA vaccine segment leads in performance, attributed to its rapid development capabilities and adaptability to various pathogens. DNA vaccines follow as the second highest performing segment, benefiting from their stability and ease of production. The adjuvant technologies sub-segment within the delivery systems segment is gaining prominence, enhancing vaccine efficacy and immunogenicity. Viral vector vaccines are also experiencing significant traction, particularly for their ability to elicit strong immune responses. Nanoparticle-based delivery systems are emerging as a promising area, offering targeted and controlled vaccine delivery. Innovations in cold chain logistics and storage solutions further support the market's expansion, ensuring vaccine potency and accessibility. The integration of digital health technologies, such as AI-driven analytics and data management platforms, is optimizing vaccine distribution and monitoring, presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeRecombinant Vaccines, DNA Vaccines, RNA Vaccines, Subunit Vaccines, Vector-Based Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Synthetic Vaccines
ProductVaccine Formulations, Adjuvants, Vaccine Delivery Devices, Vaccine Packaging, Vaccine Storage Solutions
TechnologyNanoparticle Technology, Virus-Like Particles, Conjugate Technology, Gene Editing, Synthetic Biology, Reverse Vaccinology
ApplicationInfectious Diseases, Cancer Vaccines, Allergy Vaccines, Autoimmune Disorders, Neurological Disorders
End UserHospitals, Clinics, Research Institutes, Biopharmaceutical Companies, Government Organizations
ComponentAntigens, Stabilizers, Preservatives, Adjuvants
DeviceNeedle-Free Injectors, Microneedle Patches, Oral Delivery Systems, Inhalation Devices
ProcessFermentation, Cell Culture, Purification, Formulation
DeploymentOn-Premise, Cloud-Based, Hybrid
SolutionsCold Chain Management, Vaccine Tracking Systems

The Next-Generation Vaccination Technologies Market is characterized by a dynamic distribution of market share, with various companies vying for dominance through strategic pricing and innovative product launches. The competitive landscape is marked by a surge in new entrants, each offering cutting-edge solutions that promise enhanced efficacy and safety. Established players are leveraging their market presence to introduce advanced vaccines, capitalizing on the growing demand for effective immunization options. This competitive drive is further fueled by the need to address emerging infectious diseases, prompting continuous innovation and adaptation. In the realm of competition benchmarking, major pharmaceutical companies are evaluated on their technological advancements and strategic collaborations. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe shaping market entry and expansion. The market is witnessing a shift towards personalized vaccination solutions, driven by advancements in genetic research and biotechnology. The integration of AI and data analytics is enhancing vaccine development processes, positioning companies at the forefront of technological innovation. This landscape presents lucrative opportunities for stakeholders willing to navigate regulatory complexities and invest in R&D.

Geographical Overview:

The Next-Generation Vaccination Technologies Market is witnessing profound growth across several key regions, each exhibiting unique dynamics. North America is at the forefront, driven by robust research and development activities and significant investments in innovative vaccine technologies. The presence of leading biotechnology firms and a strong healthcare infrastructure further propels this growth. In Europe, the market is buoyed by substantial funding for vaccine research and a focus on public health initiatives. The region's commitment to combating infectious diseases enhances its market potential. Asia Pacific is experiencing rapid expansion, fueled by increasing healthcare expenditures and government support for vaccination programs. Emerging economies like China and India are pivotal, with rising demand for advanced vaccines. Latin America and the Middle East & Africa present promising growth pockets. In Latin America, improving healthcare infrastructure and increased awareness drive market expansion. Meanwhile, the Middle East & Africa are investing in vaccination technologies to address public health challenges and bolster healthcare resilience.

Global tariffs and geopolitical tensions are intricately influencing the Next-Generation Vaccination Technologies Market. Japan and South Korea are strategically enhancing domestic R&D capabilities to mitigate reliance on foreign vaccine inputs, while China is accelerating its push for self-sufficiency amidst export controls and tariffs. Taiwan, with its robust biotech sector, remains pivotal yet vulnerable due to geopolitical frictions. The overarching market is witnessing robust growth driven by technological advancements, though supply chain disruptions and trade disputes pose challenges. By 2035, the market is expected to evolve with increased regional collaborations and innovation. Middle East conflicts exacerbate global supply chain vulnerabilities, potentially elevating energy costs and impacting production logistics, thereby necessitating strategic resilience planning across the vaccination technology landscape.

Key Trends and Drivers:

The Next-Generation Vaccination Technologies Market is experiencing robust growth driven by advancements in biotechnology and increased investment in research and development. Key trends include the development of mRNA vaccines, which have gained prominence due to their rapid development and high efficacy. The rise of personalized vaccines tailored to individual genetic profiles is also gaining traction, offering more effective immunization strategies. Another significant trend is the integration of artificial intelligence and machine learning in vaccine development, which accelerates the identification of potential vaccine candidates. Drivers include the urgent need for pandemic preparedness and the global push for more efficient and scalable vaccine production methods. The increasing prevalence of infectious diseases and the demand for innovative vaccination solutions are further propelling market growth. Opportunities abound in emerging markets where vaccination coverage is expanding, driven by government initiatives and international collaborations. Companies investing in next-generation platforms and technologies are well-positioned to capitalize on these emerging opportunities. Moreover, the focus on improving vaccine distribution and storage, particularly in remote areas, is creating avenues for growth. As the world continues to prioritize health security, the Next-Generation Vaccination Technologies Market is poised for sustained expansion.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Component
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Recombinant Vaccines
    • 4.1.2 DNA Vaccines
    • 4.1.3 RNA Vaccines
    • 4.1.4 Subunit Vaccines
    • 4.1.5 Vector-Based Vaccines
    • 4.1.6 Live Attenuated Vaccines
    • 4.1.7 Inactivated Vaccines
    • 4.1.8 Synthetic Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Vaccine Formulations
    • 4.2.2 Adjuvants
    • 4.2.3 Vaccine Delivery Devices
    • 4.2.4 Vaccine Packaging
    • 4.2.5 Vaccine Storage Solutions
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Nanoparticle Technology
    • 4.3.2 Virus-Like Particles
    • 4.3.3 Conjugate Technology
    • 4.3.4 Gene Editing
    • 4.3.5 Synthetic Biology
    • 4.3.6 Reverse Vaccinology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Infectious Diseases
    • 4.4.2 Cancer Vaccines
    • 4.4.3 Allergy Vaccines
    • 4.4.4 Autoimmune Disorders
    • 4.4.5 Neurological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
    • 4.5.5 Government Organizations
  • 4.6 Market Size & Forecast by Component (2020-2035)
    • 4.6.1 Antigens
    • 4.6.2 Stabilizers
    • 4.6.3 Preservatives
    • 4.6.4 Adjuvants
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Needle-Free Injectors
    • 4.7.2 Microneedle Patches
    • 4.7.3 Oral Delivery Systems
    • 4.7.4 Inhalation Devices
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Fermentation
    • 4.8.2 Cell Culture
    • 4.8.3 Purification
    • 4.8.4 Formulation
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-Premise
    • 4.9.2 Cloud-Based
    • 4.9.3 Hybrid
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Cold Chain Management
    • 4.10.2 Vaccine Tracking Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Component
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Deployment
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Component
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Deployment
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Component
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Deployment
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Component
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Deployment
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Component
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Deployment
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Component
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Deployment
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Component
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Deployment
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Component
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Deployment
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Component
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Deployment
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Component
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Deployment
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Component
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Deployment
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Component
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Deployment
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Component
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Deployment
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Component
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Deployment
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Component
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Deployment
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Component
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Deployment
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Component
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Deployment
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Component
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Deployment
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Component
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Deployment
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Component
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Deployment
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Component
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Deployment
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Component
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Deployment
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Component
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Deployment
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Component
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Deployment
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Cure Vac
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Valneva
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Novavax
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Inovio Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Vaxart
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Geo Vax Labs
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Moderna
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Bio NTech
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Dynavax Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Bavarian Nordic
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Arcturus Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Immunomic Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Medicago
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Altimmune
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Emergent Bio Solutions
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gritstone Oncology
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Sorrento Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Translate Bio
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Vir Biotechnology
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Icosavax
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us